-
Product Insights
Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glioblastoma Multiforme (GBM) Clinical Trial Report Overview A total of 2,375 Glioblastoma Multiforme (GBM) clinical trials were conducted as of February 2024. The GBM clinical trial report provides a comprehensive understanding of the GBM clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
NewAnaplastic Astrocytoma – Drugs In Development, 2024
Empower your strategies with our Anaplastic Astrocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic astrocytoma is a grade III tumor that accounts for 2% of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking,...
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Product Insights
NewAnaplastic Oligoastrocytoma – Drugs In Development, 2024
Empower your strategies with our Anaplastic Oligoastrocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the...
-
Sector Analysis
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs. There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules,...
-
Sector Analysis
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional GBM therapies was $630 million in 2021. High usage of dendritic cell vaccines and oncolytic viruses that demonstrate significant survival advantages will drive market growth during the forecast period. Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Glioblastoma Multiforme (GBM) – Cell...
-
Sector Analysis
Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030
Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain's neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients...